menu
    • menu
    [{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Cowellnex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Cowellnex","highestDevelopmentStatusID":"2","companyTruncated":"Siolta Therapeutics \/ Cowellnex"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Genome \/ Gilead Sciences"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Medicine \/ Galapagos"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"2","companyTruncated":"Sinopia Biosciences \/ NIDCR"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Cowellnex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Siolta Therapeutics and Cowellnex Enter Joint Research Agreement

                            Details : Under the agreement, Siolta will develop live biotherapeutic products with joint research program with Cowellnex for treating necrotizing enterocolitis in infants.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            January 29, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Cowellnex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sinopia Biosciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Sinopia Biosciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : NIDCR

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Sinopia Gets SBIR Phase II Grant For Oral Mucositis Research

                            Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : NIDCR

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sonoma Biotherapeutics Receives $45M Regeneron Milestone

                            Details : The collaboration will bring together Regeneron’s VelociSuite technologies to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $75.0 million

                            April 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kallyope

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Kallyope

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets f...

                            Details : The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novome Biotechnologies

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Novome Biotechnologies

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : $605.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammat...

                            Details : Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : $15.0 million

                            October 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : $605.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Scipher Medicine

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Scipher Medicine

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease

                            Details : Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 08, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Codexis

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Codexis

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDX-7108

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinica...

                            Details : The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder.

                            Product Name : CDX-7108

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 01, 2020

                            Lead Product(s) : CDX-7108

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Second Genome

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Second Genome

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $1,538.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease...

                            Details : Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $38.0 million

                            June 04, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $1,538.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celsius Therapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Celsius Therapeutics

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflamma...

                            Details : Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 07, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth